Collecting data on rare and complex tumors in the thoraco-abdominal region
Official title: Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District - Observational Study With Retrospective and Prospective Phase
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06872853 · Data updated 2026-11-12
This study is collecting information on rare and complex tumors in the chest and abdomen to better understand how they are diagnosed, treated, and followed up over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1100 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 2 sites (Bologna, BO and 1 other locations) |
| Status | Recruiting |
| Started | September 29, 2017 |
| Main results expected | November 30, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | March 12, 2025 |
| Trial ID | NCT06872853 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a histologic diagnosis of rare or highly complex malignant neoplasms.
✕Probably not a fit
Patients without a histologic diagnosis of rare malignant neoplasms will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather structured data regarding the diagnosis, treatment, and follow-up of rare and complex malignant neoplasms. It includes a retrospective component that collects data from patients treated at the IRCCS Azienda Ospedaliero-Universitaria di Bologna from January 1, 2000, to September 28, 2017, as well as a prospective component extending to December 31, 2025. The study focuses on understanding the clinical pathways and outcomes associated with these rare tumors.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of rare malignant neoplasms, leading to improved patient outcomes.
How similar studies have gone: While there may be limited studies specifically targeting rare tumors, observational studies in oncology have shown success in improving treatment protocols and patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with histologic diagnosis of rare or highly complex malignant neoplasm * informed consent Exclusion Criteria: * none
Where it's running
-
Oncology Unit, IRCCS AOUBO Policlinico di S. Orsola
Bologna, Bo, Italy Recruiting -
Thoracic Surgery Unit
Bologna, Bo, Italy Recruiting
Study contacts
- Principal investigator: Maria A Pantaleo, MD — Oncology Unit, IRCCS AOUBO
- Study coordinator: Maria A Pantaleo, MD
- Email: maria.pantaleo@unibo.it
- Phone: +39 051 214
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted therapy for rare cancers
This study is testing whether a personalized cancer treatment based on specific gene changes can help people with rare and hard-to-treat cancers feel better and improve their outcomes.
-
Registry for patients with advanced rare cancers in Asia
This study is collecting information from patients with advanced rare cancers in Asia to see how different treatments work and to find better, personalized options for their care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.